NCT00298987

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

Study of Dasatinib (BMS-354825) in Subjects With Chronic Myelogenous Leukemia With Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.

Conditions

• Leukemia, Myeloid, Chronic
• Leukemia, Lymphocytic, Acute, L2

Interventions

Type	Name	Description
DRUG	Dasatinib	Tablets, Oral, 70 mg, Twice daily, 2 months.

Timeline

• Start date: 2006-02-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2006-03-06
• Last updated: 2010-02-08

Locations

35 sites across 2 countries: United States, Canada